Phase I, Open-Label, Dose-Escalation Study of the Combination of Sorafenib and Vorinostat in Poor-Risk Acute Myelogenous Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS).

Trial Profile

Phase I, Open-Label, Dose-Escalation Study of the Combination of Sorafenib and Vorinostat in Poor-Risk Acute Myelogenous Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS).

Completed
Phase of Trial: Phase I

Latest Information Update: 22 Sep 2014

At a glance

  • Drugs Sorafenib (Primary) ; Vorinostat (Primary)
  • Indications Acute myeloid leukaemia; Myelodysplastic syndromes
  • Focus Adverse reactions
  • Most Recent Events

    • 22 Sep 2014 Status changed from active, no longer recruiting to completed.
    • 15 Oct 2012 Planned end date changed from 1 Apr 2012 to 1 Apr 2013 as reported by ClinicalTrials.gov.
    • 30 Mar 2012 Planned end date changed from 1 Apr 2014 to 1 Apr 2012 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top